Smallpox drug makers receive new orders as the monkeypox spreads.
Smallpox drug companies Siga Technologies and Chimerix Inc said Thursday they have received new orders for their antiviral drugs, which are expected to increase the risk of infection worldwide. Will be used as a treatment for monkeypox.
More than 3,000 confirmed cases of monkeypox – belonging to the family of orthopox viruses including smallpox and cowpox – have been reported from 40 countries where the disease is not endemic.
With the increase in numbers, the World Health Organization is about to decide whether to declare Monkey Pox a World Health Emergency.
Siga received orders for approximately 13 million for its oral smallpox drug Tpoxx, and Chimerix received orders for 9.3 million for its drug Tembexa.
- Shares of Siga rose 5.1%, while shares of Chimerix rose 5%.
- UK inflation hits new 40-year high of 9.1% as food and energy price surge persists
Chimerix, which agreed to sell the drug rights to Emergency Bio Solutions in May, said Thursday that the new orders contract is expected to be completed before the sale.
Sega’s drug is approved in the European Union for the treatment of diseases including Tpoxx, smallpox, monkeypox, and cowpox, while it is only approved for the treatment of smallpox in the United States and Canada.
Phil Gomez, Siga’s chief executive officer, said: “We expect that a portion of the oral Tpoxx courses offered under these orders will be used to treat active monkeypox cases.”